Overnight Market report, page-2105

“I have been following this company and stock for last 2-3 years and the biggest impediment for realizing true value of their assets in the stock market is the Australian listing. If you watch how it trades in Australia, every single breakout on NASDAQ has been killed by Aussie traders.With all the recent impressive results and breadth of their pipeline this stock should be trading at $8 if not more.Australian listing is simply killing this stock. It trades in Australia as IMM.AX in pennies (31.5 Aussie pennies latest closing price) and 800+ million outstanding shares. In my opinion it trades like a penny stock and with 800+ million shares outstanding it is very easy to manipulate and control the price.What premium oncology biotech with mature pipeline does this? I am simply dumbfounded why company continues listing in Australia especially as penny stock. It just does not make any sense”

fair comments, I'm sure this happens to a lot of asx stocks too, ugly ASX and aussie traders.